Clinical Trials Directory

Trials / Unknown

UnknownNCT02627521

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
260 (estimated)
Sponsor
Unity Health Toronto · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The administration of Ticagrelor have demonstrated superiority to Clopidogrel in patients presenting with acute coronary syndrome (ACS) and remains a first line therapy as an adjunct to aspirin for patients admitted with ACS. The patient population treated with Ticagrelor at an early time point includes non ST elevation myocardial (NSTEMI) patients and those undergoing primary angioplasty for ST elevation myocardial infarction (STEMI). It is estimated that 10-15% of patients presenting with ACS have advanced coronary artery disease requiring Coronary Artery Bypass Surgery (CABG). The treatment guidelines recommend a delay of 5-7 days for CABG surgery in these patients for normalization of Ticagrelor induced platelet inhibition to reduce the risk of peri-operative bleeding. This delay may expose these high risk patients to adverse cardiac events while waiting for Ticagrelor effect to wean off. Furthermore, this empirical application of 5-7 day delay in all patients may be unnecessary due to the significant inter individual variability in response to Ticagrelor. There is limited data to determine the optimum timing of CABG surgery in ACS patients treated with Ticagrelor. The present study will determine the optimum timing of CABG in ACS patients treated with a loading and/or maintenance dose of Ticagrelor.

Conditions

Interventions

TypeNameDescription
PROCEDUREPRU guided CABGCoronary Artery Bypass Surgery
PROCEDURECABG per standard of careCoronary Artery Bypass Surgery
DEVICEVerifyNow assayPlatelet reactivity Units by VerifyNow assay
DRUGTicagrelorTicagrelor administration prior to randomization

Timeline

Start date
2015-07-01
Primary completion
2017-08-01
Completion
2017-08-01
First posted
2015-12-11
Last updated
2017-02-16

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02627521. Inclusion in this directory is not an endorsement.